A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.
Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y, Soh S, Lee WH, Huang JW, Allen JC, Woo XY, Nagarajan N, Kumar V, Thalamuthu A, Poh WT, Ang AL, Mya HT, How GF, Yang LY, Koh LP, Chowbay B, Chang CT, Nadarajan VS, Chng WJ, Than H, Lim LC, Goh YT, Zhang S, Poh D, Tan P, Seet JE, Ang MK, Chau NM, Ng QS, Tan DS, Soda M, Isobe K, N?then MM, Wong TY, Shahab A, Ruan X, Cacheux-Rataboul V, Sung WK, Tan EH, Yatabe Y, Mano H, Soo RA, Chin TM, Lim WT, Ruan Y, Ong ST. A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012 Mar 18; 18(4):521-8.
-
Adult
-
Aged
-
Aged, 80 and over
-
Annexins
-
Apoptosis
-
Apoptosis Regulatory Proteins
-
BH3 Interacting Domain Death Agonist Protein
-
Carcinoma, Non-Small-Cell Lung
-
Cell Line, Tumor
-
Cohort Studies
-
Dose-Response Relationship, Drug
-
Drug Resistance, Neoplasm
-
Enzyme-Linked Immunosorbent Assay
-
Exons
-
Female
-
Follow-Up Studies
-
Gene Expression Regulation, Neoplastic
-
Gene Frequency
-
Genotype
-
Humans
-
International Cooperation
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
-
Lung Neoplasms
-
Male
-
Membrane Proteins
-
Middle Aged
-
Polymorphism, Genetic
-
Protein Isoforms
-
Protein Kinase Inhibitors
-
Proto-Oncogene Proteins
-
RNA, Small Interfering
-
Sequence Deletion
-
Statistics, Nonparametric
-
Transfection